Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

IDYAIDEAYA BiosciencesSigning up patients

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Metastatic Uveal Melanoma · Cutaneous Melanoma · Colorectal Cancer · Other Solid Tumors

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
336 (planned)
Started
Jun 28, 2019
Main results expected
Jan 29, 2027
Fully finished
Jun 15, 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Dose-limiting Toxicity (DLT)

    Measured over: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

  • Incidence of Adverse Events

    Measured over: Approx. 8 months

  • Maximum Tolerated Dose (MTD)

    Measured over: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

  • Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Measured over: Approx. 6 months

  • Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Measured over: Approx. 6 months

  • Plasma Concentrations of Crizotinib administered in combination with IDE196

    Measured over: Approx. 6 months

  • Plasma Concentrations of Binimetinib administered in combination with IDE196

    Measured over: Approx. 6 months

  • Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment

    Measured over: Approx. 8 months

  • Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment

    Measured over: Approx. 8 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT03947385 · record last updated 2026-06-08 · checked 2026-11-09 15:42 UTC

See the official record on ClinicalTrials.gov (NCT03947385) ↗